Evidence map›Paper›PMID 41593341›Full record

ArticleScientific reports2026

Contrast-enhanced T

Saikat Maiti, Santosh K Yadav, Maya Teitz, Esteban Velarde, Shana Lee, Kristen Lecksell, Adnan Bibic, Ethel J Ngen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Saikat Maiti *Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Santosh K Yadav *Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Maya TeitzRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Esteban VelardeDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA.
Shana LeeDepartment of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Kristen LecksellDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Adnan BibicRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Ethel J NgenRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA. engen1@jhmi.edu.

Funding

Image-guided combination therapies for radiotherapy-induced neurocognitive impairment in pediatric brain tumor survivorsR01CA262887 · NCI · JOHNS HOPKINS UNIVERSITY · PI NGEN, ETHEL JOSO · 2021 to 2025
$2.8M
MRI biosensors and complementary drug nanocarriers for effective image-guided drug delivery and early tumor response assessment of pediatric medulloblastomasR21HD097357 · NICHD · JOHNS HOPKINS UNIVERSITY · PI NGEN, ETHEL JOSO · 2019 to 2020
$465k
NCI NIH HHS R01 CA262887NICHD NIH HHS R21 HD097357The National Cancer Institute (NCI) and the Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) of the National Institutes of Health Awards Number R01CA262887 and R21HD097357
6 · The paper itself

Abstract

Radiotherapy-induced brain injury (RIBI) is a chronic side effect that affects brain tumor survivors treated with radiotherapy. Neuroinflammation is a key contributor to RIBI. Thus, imaging methods capable of noninvasively monitoring neuroinflammation are needed. Although positron emission tomography (PET)-based radiotracers exist for imaging neuroinflammation, PET involves ionizing radiation which could be detrimental to pediatric patients already facing the risk of RIBI. Here, we evaluated the feasibility of developing contrast-enhanced T

Indexed as

Brain InjuriesMagnetic Resonance ImagingNeuroinflammatory DiseasesPositron-Emission TomographyPyrazolesPyrimidinesRadiation InjuriesAcetamidesAnimalsBiomarkersBrainCarbon RadioisotopesContrast MediaFemaleHeterocyclic CompoundsMiceAcetamidesBiomarkersCarbon-11Carbon RadioisotopesContrast MediaHeterocyclic CompoundsN,N-diethyl-2-(2-(4-methoxyphenyl)-5,7-dimethyl-pyrazolo(1,5-a)pyrimidin-3-yl)-acetamideOrganometallic CompoundsPyrazolesPyrimidinesBrain injuryContrast-enhanced T1-weighted MRI biomarkers of radiotherapy-induced brain injuryImaging biomarkers of neuroinflammationNoninvasive biomarkers of neuroinflammationPET biomarkers of neuroinflammationPredictive biomarkers of neuroinflammationRadiation injury

Identifiers

PMID41593341
PMCPMC12909786

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.